Prostate cancer: thalidomide for prostate cancer: is there progress?
Upon its 'reinvention', thalidomide was quickly applied to 'microenvironment-dependent' diseases such as multiple myeloma, yet its role in the solid tumor spectrum has not been validated. A report into recurrent prostate cancer by Figg et al. shows that thalidomide can reduce time to PSA progression in patients treated with androgen deprivation therapy.
Eleni
E
Efstathiou
Christopher J
CJ
Logothetis
D002986:Clinical Trials as Topic / Q000639:trends; D018450:Disease Progression; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D013792:Thalidomide / Q000627:therapeutic use*
D007987:Gonadotropin-Releasing Hormone; D013792:Thalidomide